Aquestive Price To Operating Cash Flows Ratio from 2010 to 2024
| AQST Stock | USD 4.51 0.23 4.85% |
Price To Operating Cash Flows Ratio | First Reported 2010-12-31 | Previous Quarter (19.39) | Current Value (18.42) | Quarterly Volatility 29.50084008 |
Check Aquestive Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Aquestive Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 9.5 M, Selling General Administrative of 43.5 M or Total Revenue of 48.2 M, as well as many indicators such as Price To Sales Ratio of 3.76, Dividend Yield of 0.0 or Days Sales Outstanding of 47.57. Aquestive financial statements analysis is a perfect complement when working with Aquestive Therapeutics Valuation or Volatility modules.
Aquestive | Price To Operating Cash Flows Ratio |
Latest Aquestive Therapeutics' Price To Operating Cash Flows Ratio Growth Pattern
Below is the plot of the Price To Operating Cash Flows Ratio of Aquestive Therapeutics over the last few years. It is Aquestive Therapeutics' Price To Operating Cash Flows Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Aquestive Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Price To Operating Cash Flows Ratio | 10 Years Trend |
|
Price To Operating Cash Flows Ratio |
| Timeline |
Aquestive Price To Operating Cash Flows Ratio Regression Statistics
| Arithmetic Mean | (22.99) | |
| Geometric Mean | 19.54 | |
| Coefficient Of Variation | (128.32) | |
| Mean Deviation | 23.44 | |
| Median | (19.39) | |
| Standard Deviation | 29.50 | |
| Sample Variance | 870.30 | |
| Range | 103 | |
| R-Value | 0.56 | |
| Mean Square Error | 643.37 | |
| R-Squared | 0.31 | |
| Significance | 0.03 | |
| Slope | 3.69 | |
| Total Sum of Squares | 12,184 |
Aquestive Price To Operating Cash Flows Ratio History
About Aquestive Therapeutics Financial Statements
Aquestive Therapeutics shareholders use historical fundamental indicators, such as Price To Operating Cash Flows Ratio, to determine how well the company is positioned to perform in the future. Although Aquestive Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Aquestive Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Aquestive Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Price To Operating Cash Flows Ratio | (19.39) | (18.42) |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Aquestive Stock Analysis
When running Aquestive Therapeutics' price analysis, check to measure Aquestive Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aquestive Therapeutics is operating at the current time. Most of Aquestive Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aquestive Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aquestive Therapeutics' price. Additionally, you may evaluate how the addition of Aquestive Therapeutics to your portfolios can decrease your overall portfolio volatility.